Chaperone Technologies

Chaperone Technologies is a biopharmaceutical company dedicated to developing a new class of antibiotics to combat multi-drug resistant (MDR) bacterial infections. The company's proprietary technology focuses on proline-rich antimicrobial peptides (PrAMPs) that specifically target and inhibit bacterial chaperones. Their primary target is Chaperone protein DnaK, a protein essential for proper protein folding and bacterial viability. By disrupting these critical bacterial processes, Chaperone Technologies aims to provide effective treatments for life-threatening Gram-negative pathogens. The company's lead programs are designed to bypass existing resistance mechanisms, offering a novel approach to infectious disease management. Founded on research from the Wistar Institute, the company has historically operated out of Philadelphia's biotech corridor.